Introduction
Drug-resistant strains of tuberculosis (TB) pose a serious threat to prevention and control efforts. Although drugresistant TB has not yet been identified as a major problem in Canada, its potential to become an issue is high because of the frequency with which Canadians travel abroad.
In 1998, in response to a growing concern about TB drug resistance worldwide, thegovernment of Canada , in partnership with the Canadian Tuberculosis Laboratory Technical Network (CTLTN)-a network of provincial and territorial TB laboratories across Canada with representation from their respective technical or scientific TB programs leads-established the Canadian Tuberculosis Laboratory Surveillance System (CTBLSS) to monitor trends and patterns in tuberculosis drug resistance in Canada over time. This article provides an overview of the most recent data on TB drug resistance in Canada as well as details on the overall level of TB drug resistance in Canada for the period 2003 to 2013, focusing, in particular, on 2013 (1).
Background
The CTBLSS is an isolate-based surveillance system designed to collect timely data on TB drug resistance across Canada. Information on the results of all unique isolates tested for drug resistance during the previous calendar year are voluntarily submitted by provincial TB laboratories to PHAC for inclusion in the CTBLSS. The primary objectives of the CTBLSS are:
 To describe the number of drug-resistant TB isolates in Canada on an annual basis by resistance pattern and by originating province/territory, and by sex and age.
 To monitor trends in drug-resistant TB in Canada over time by originating province/territory, and by sex and age.
TB drug resistance is determined through susceptibility testing of cultures grown from clinical specimens obtained from individuals with culture-positive TB (2 
Definitions of different drug-resistant patterns to tuberculosis
Monoresistance  Resistance to only one first-line anti-TB drug
Polyresistance (other patterns)
 Resistance to more than one first-line anti-TB drug, not including the isoniazid and rifampin combination of MDR-TB
Multidrug-resistant tuberculosis (MDR-TB)
 TB due to bacteria resistant to isoniazid and rifampin with or without resistance to other anti-TB drugs
Extensively drug-resistant TB (XDR-TB)
 TB due to bacteria resistant to isoniazid and rifampin and any fluoroquinolone and at least one of the three injectable second-line anti-TB drugs (amikacin, capreomycin or kanamycin)
Methods
At the beginning of each calendar year, participating laboratories voluntarily submit drug susceptibility testing (DST) results for all MTBC isolates tested in the previous year. Although some laboratories report results for M. bovis BCG strain, these are excluded from this article.
The following information is submitted to PHAC: the date the isolate or specimen was received at the laboratory and its identification number; the province/territory where the isolate was tested in the province or territory where it originates from; the sex, date of birth (or age) of the person the isolate came from; and the drug susceptibility results. 
Results

Reporting for 2013
In 2013, TB DST results for 1,397 isolates were reported to PHAC. Of these, 762 (54%) were reported as MTBC where the species was known (750 were M. tuberculosis; 8 were M. africanum and 4 were M. bovis) and 618 (44%) were MTBC of an unknown species. Seventeen (1.2%) isolates were identified as M. bovis BCG and were excluded from further analyses (data not shown). As a result, laboratory results for 1,380 isolates were analyzed for this article. Of these, 68% of all the reported isolates originated from the three largest provinces, British Columbia, Ontario and Quebec. Figure 1 provides a breakdown of the number of isolates tested by province or territory of origin of the isolate. 
Monoresistance
In 2013, of the 112 TB isolates reported to be resistant to at least one of the four first-line drugs, the majority, 93 (83%), were monoresistant. Of these, 74 (80%) were isoniazid-resistant, 17 (18%) were pyrazinamide-resistant, and 2 (2%) were rifampin-resistant. No isolates were identified as ethambutol-monoresistant. 
Multidrug-resistance
In 2013, fifteen isolates were resistant to bothisoniazid and rifampin (classifying these isolates as MDR-TB at least), six (40%) of which were resistant only to isoniazid and rifampin. In addition to being resistant to isoniazid and rifampin, three of these fifteen (20%) were also resistant to ethambutol, one (6%) to pyrazinamide, and five (33%) to all first-line drugs. An additional four isolates (0.3%) were resistant to two or more of the first-line drugs excluding the isoniazid and rifampin combination.
Extensively drug-resistance
To rule out XDR-TB, all fifteen isolates that were resistant to both isoniazid and rifampin were subsequently tested for resistance to select second-line drugs. Of these, twelve isolates were susceptible to both the injectable agents and the fluoroquinolones, one was resistant to an injectable, and one was resistant to a fluoroquinolone. As a result, these fourteen isolates (1.0% of all isolates tested) were classified as MDR-TB. The remaining isolate was resistant to at least one of the injectables and to a fluoroquinolone, which classified it as XDR-TB (0.1% of all isolates tested). Thus, results from additional second-line testing in 2013 identified fourteen isolates as MDR-TB and one as XDR-TB (Figure 3 ). 1 Multidrug-resistant TB (MDR-TB) is TB that is resistant to at least isoniazid and rifampin, but which does not meet the definition of XDR-TB. 2 Extensively drug-resistant TB (XDR-TB) is TB that is resistant to at least the two best first-line drugs, isoniazid and rifampin, plus resistant to second-line drugs, including any fluoroquinolone and at least one of three injectable agents, amikacin, capreomycin and kanamycin.
Geographic distribution
In 2013, 68% of all the reported isolates originated from the three largest provinces, British Columbia, Ontario and Quebec. All isolates from Northwest Territories, Nunavut, Yukon, and Newfoundland and Labrador were fully susceptible to all the first-line drugs tested. Prince Edward Island did not report a case of TB in 2013 and no 
Demographic data
In 2013, sex information was reported for all but two individuals from whom isolates were obtained, and age or date of birth was available for all. Males accounted for 55% of all reports. Figure 4 shows the number of isolates tested by age group and sex.
Figure 4: All isolates tested by sex and age group, 2013
Of the 112 isolates for which any drug-resistance pattern was identified, 23% were from individuals between the ages of 24 and 34 years and 21% were from individuals 45 to 54 years of age. Less than 2% of isolates were from individuals under 15 years of age. All MDR-TB isolates were from individuals between the ages of 15 and 64 years. There were no MDR-TB cases reported for individuals less than 15 years of age or over 65 years of age. Females accounted for 56% of the isolates showing any resistance and 67% (10/15) of the isolates with resistance to both isoniazid and rifampin. 1 Multidrug-resistant TB (MDR-TB) is TB that is resistant to at least isoniazid and rifampin, but which does not meet the definition of XDR-TB. 2 Extensively drug-resistant TB (XDR-TB) is TB that is resistant to at least the two best first-line drugs, isoniazid and rifampin, plus resistant to second-line drugs, including any fluoroquinolone and at least one of three injectable agents, amikacin, capreomycin and kanamycin.
Discussion
TB drug resistance in Canada remains well below the global average. Over the last 11 years, the percentage of isolates resistance to one or more of the first-line medications has decreased from 10.5% in 2003 to 8.1% in 2013.
Organisms resistant to both isoniazid and rifampin, a resistance pattern defined as multidrug-resistant TB (MDR-TB); pose a considerable challenge to treatment and prevention efforts because effective anti-tuberculosis drugs are limited. Data published by the World Health Organization (WHO) show that globally, in 2012, about 3.6% (95% CI: 2.1%-5.1%) of new TB cases and 20.2% (95% CI: 13.3%-27.2%) of previously treated TB cases were MDR-TB (4). In Canada, overall MDR-TB rate is 1.1%.
These data need to be considered in light of some limitations. Given the minimal identifying information available for each isolate (age and sex), it is possible that multiple records from one individual could be included in the database. However, this bias is believed to be minimal.
Typically, only isolates with MDR-TB or other extensive resistance patterns will undergo drug sensitivity testing to select second-line drugs. Although the Clinical and Laboratory Standards Institute recommends that isoniazidmonoresistant isolates, as well as other poly-resistant, non-MDR isolates, be tested for second-line drug resistance, this is not universally done in Canada. Other isolates which are not MDR-TB may be resistant to a fluoroquinolone because of the widespread use of these antibiotics for other respiratory infections. To some extent, this limits our understanding of the emergence of second-line resistance within Canada. The demographic and clinical data collected through the CTBLSS are minimal. As such, no differentiation can be made between primary and secondary/acquired drug resistance, nor can differentiation be made between resistance patterns for new cases versus re-treatment cases. However, the Tuberculosis in Canada report also presents case-based data on primary and acquired drug resistance in Canada and, combined with the Tuberculosis: Drug Resistance in Canada Report, provides a comprehensive overview of TB-case and drugresistance surveillance data from a national perspective.
Data collected to date indicate that the presence of TB drug resistance in Canada is below the global average and that it has remained relatively stable since reporting began. With growing worldwide concern about drug resistance and the emergence of XDR-TB, however, the CTBLSS remains vital to the monitoring of TB drug resistance in Canada.
